


We claim:

1. The compound of formula I or pharmaceutically acceptable esters, ethers, and/or salts thereof:



wherein:

Q is selected from the group consisting of -O- and -N(R)-;

R is selected from the group consisting of -H and -C<sub>1-6</sub>alkyl;

10 Z is selected from the group consisting of -C<sub>1-6</sub>alkyl-O- and  
-C<sub>1-4</sub>alkyl-cycloalkyl-O-; and

Y is selected from the group consisting of tetrazoyl, oxazoyl, thiazoyl,  
pyridyl, N-oxo-pyridyl, pyrimidinyl, and pyrazinyl; each valence permitting  
unsubstituted, mono- or polysubstituted with one or more instances selected from  
the group consisting of halo, -OR, -NR<sub>2</sub>, -SR, -C<sub>1-6</sub>alkyl, -CO<sub>2</sub>H, -CO<sub>2</sub>Ph, and  
15 -CO<sub>2</sub>C<sub>1-6</sub>alkyl.

2. The compound of claim 1 or pharmaceutically acceptable esters, ethers, and/or salts thereof, wherein:

Q is -N(R)-;


20 R is selected from the group consisting of -H and -C<sub>1-6</sub>alkyl;

Z is selected from the group consisting of -C<sub>1-6</sub>alkyl-O- and  
-C<sub>1-4</sub>alkyl-cycloalkyl-O-; and

Y is selected from the group consisting of tetrazoyl, oxazoyl, thiazoyl,  
pyridyl, N-oxo-pyridyl, pyrimidinyl, and pyrazinyl; valence permitting  
25 unsubstituted, mono- or polysubstituted with one or more instances selected from  
the group consisting of halo, -OR, -NR<sub>2</sub>, -SR, -C<sub>1-6</sub>alkyl, -CO<sub>2</sub>H, -CO<sub>2</sub>Ph, and  
-CO<sub>2</sub>C<sub>1-6</sub>alkyl.

3. The compound of claim 2 or pharmaceutically acceptable esters, ethers, and/or salts thereof, wherein Z is -C<sub>1-6</sub>alkyl-O-.
4. The compound of claim 3 or pharmaceutically acceptable esters, ethers, and/or salts thereof, wherein Z is -*n*-propyl-O-.
5. The compound of claim 4 or pharmaceutically acceptable esters, ethers, and/or salts thereof, wherein Y is pyridyl.
6. The compound of claim 1 or pharmaceutically acceptable esters, ethers, and/or salts thereof, wherein:
- Q is O;
- R is selected from the group consisting of -H and -C<sub>1-6</sub>alkyl;
- Z is selected from the group consisting of -C<sub>1-6</sub>alkyl-O- and -C<sub>1-4</sub>alkyl-cycloalkyl-O-; and
- Y is selected from the group consisting of tetrazoyl, oxazoyl, thiazoyl, pyridyl, N-oxo-pyridyl, pyrimidinyl, and pyrazinyl; each valence permitting unsubstituted, mono- or polysubstituted with one or more instances selected from the group consisting of halo, -OR, -NR<sub>2</sub>, -SR, -C<sub>1-6</sub>alkyl, -CO<sub>2</sub>H, -CO<sub>2</sub>Ph, and -CO<sub>2</sub>C<sub>1-6</sub>alkyl.
7. The compound of claim 6 or pharmaceutically acceptable esters, ethers, and/or salts thereof, wherein Z is -C<sub>1-6</sub>alkyl-O-.
8. The compound of claim 7 or pharmaceutically acceptable esters, ethers, and/or salts thereof, wherein Z is -*n*-propyl-O-.
9. The compound of claim 8 or pharmaceutically acceptable esters, ethers, and/or salts thereof, wherein Y is pyridyl.

10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredient the compound of formula I



5 wherein:

Q is selected from the group consisting of -O- and -N(R)-;

R is selected from the group consisting of -H and -C<sub>1-6</sub>alkyl;

Z is selected from the group consisting of -C<sub>1-6</sub>alkyl-O- and -C<sub>1-4</sub>alkyl-cycloalkyl-O-; and

10 Y is selected from the group consisting of tetrazoyl, oxazoyl, thiazoyl, pyridyl, N-oxo-pyridyl, pyrimidinyl, and pyrazinyl; each valence permitting unsubstituted, mono- or polysubstituted with one or more instances selected from the group consisting of halo, -OR, -NR<sub>2</sub>, -SR, -C<sub>1-6</sub>alkyl, -CO<sub>2</sub>H, -CO<sub>2</sub>Ph, and -CO<sub>2</sub>C<sub>1-6</sub>alkyl.

15

11. A method of treatment of a cancer in a patient, which method comprises administering to a patient a therapeutically effective amount of the compound of claim 1.

12. A method of treatment of a cancer in a patient, which method comprises  
20 administering to a patient a therapeutically effective amount of the composition of claim 9.

13. The method of claim 11, wherein the cancer is one of: carcinoma, leukemia, lymphoma, hematopoietic tumor, tumor of the central or peripheral nervous system,  
25 astrocytoma, neuroblastoma, glioma and schwannomas, melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratocanthoma, thyroid follicular cancer or Kaposi's sarcoma.

14. The method of claim 13, wherein the carcinoma is one of: carcinoma of bladder, breast, colon, kidney, liver, lung, esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, or skin, or squamous cell carcinoma.

5 15. The method of claim 14, wherein the leukemia is one of: acute lymphocytic leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, or promyelocytic leukemia.

10 16. The method of claim 14, wherein the lymphoma is one of: B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma or Burkett's lymphoma.

15